Devonian Health Group Reports Second Quarter 2024 Financial Results and Business Update
Devonian Announces Closing of a Private Placement of Units
Devonian Names Kathryn J. Gregory to Board of Directors and Grants Stock Options
Devonian Announces that its Subsidiary, Altius, Launches Authorized Generic of Dexlansoprazole (Dexilant®) in Canada
Devonian Announces a $2.16 Million Secured Term Loan Following Repayment of $3.5 Million Long Term Loan
Devonian Announces Results of Annual General and Special Shareholders' Meeting
Devonian Bolsters Intellectual Property With Issuance of U.S. Patent
Devonian Bolsters Leadership Team and Aligns Strategy
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, , is pleased to announce that the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for Devonian’s Patent application No.: 16/998.004 entitled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease”. This U.S. patent application is an addition to Devonian’s existing patent portfolio relating to thylakoids developed by the company such as PUR0110 (Thykamine™). The allowed U.S patent application is directed to a method for treating inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease in a human subject with an effective amount of active thylakoid extract.
QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that it has closed its non-brokered previously announced private placement for aggregate gross proceeds of $1,199,664.75 (the “Offering”). The Offering consisted of the issuance of 7 997 765 units of the Corporation (the “Units”) at a price of $0.15 per Unit. Each Unit consists of one subordinate voting share of the Corporation (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $0.20 per Share for a period of 24 months from the date of issuance thereof.